Simultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine;Pneumonite intersticial e miocardiopatia simultâneas induzidas por venlafaxina

Jornal Brasileiro de Pneumologia

Volumn 40, Issue 3, 2014, Pages 313-318

  Ferreira, Pedro Gonçalo ^a   Costa, Susana ^a   Dias, Nuno ^a   Ferreira, António Jorge ^a   Franco, Fátima ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Antidepressive agents; Cardiomyopathy; Dilated; Herb drug interactions; Interstitial; Lung diseases; Second generation toxicity

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; VENLAFAXINE;

ADULT; CARDIOMYOPATHIES; CASE REPORT; CHEMICALLY INDUCED; DEPRESSIVE DISORDER; FEMALE; HUMAN; LUNG DISEASES, INTERSTITIAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CARDIOMYOPATHIES; CYCLOHEXANOLS; DEPRESSIVE DISORDER; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL;

EID: 84904395577     PISSN: 18063713     EISSN: 18063756     Source Type: Journal    
DOI: 10.1590/S1806-37132014000300015     Document Type: Article

References (22)

1. Nemery B, Bast A, Behr J, Borm PJ, Bourke SJ, Camus PH, et al. Interstitial lung disease induced by exogenous agents: factors governing susceptibility. Eur Respir J Suppl. 2001; 32: 30s-42s.
2. Wijnen PA, Drent M, Nelemans PJ, Kuijpers PM, Koek GH, Neef C, et al. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity. Drug Saf. 2008; 31(12): 1125-34. http://dx. doi. org/10. 2165/0002018-200831120-00008.
3. Wijnen P, Bekers O, Drent M. Relationship between druginduced interstitial lung diseases and cytochrome P450 polymorphisms. Curr Opin Pul Med. 2010; 16(5): 496-502. http://dx. doi. org/10. 1097/MCP. 0b013e32833c06f1.
4. Drent M, Singh S, Gorgels AP, Hansell DM, Bekers O, Nicholson AG, et al. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am J Respir Crit Care Med. 2003; 167(7): 958-61. http://dx. doi. org/10. 1164/rccm. 200207-739CR.
5. Vázquez MJ, Carretero Quevedo B. Pneumonitis related to venlafaxine. Psychosomatics. 2008; 49(1): 84-5. http://dx. doi. org/10. 1176/appi. psy. 49. 1. 84.
6. Turner RC, Nelson JE, Roberts BT, Gillam DM. Venlafaxineassociated interstitial pneumonitis. Pharmacotherapy. 2005; 25(4): 626-9. http://dx. doi. org/10. 1592/phco. 25. 4. 626. 61029.
7. Borderías Clau L, Marigil Gómez MA, Val Adán P, Marcén Letosa M, Biescas López R, Garrapiz López FJ. Hypersensitivity pneumonitis due to venlafaxine [Article in Spanish]. Arch Bronconeumol. 2008; 44(10): 571-3. http://dx. doi. org/10. 1016/S1579-2129(08)60104-4.
8. Fleisch MC, Blauer F, Gubler JG, Kuhn M, Scherer TA. Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment. Eur Respir J. 2000; 15(1): 205-8. http://dx. doi. org/10. 1183/09031936. 00. 15120500.
9. Priou P, Gagnadoux F, Dehé C, Hureaux J, Pearson C, Urban T, et al. Drug-induced pneumonitis in a patient treated with venlafaxine and propanolol [Article in French]. Rev Mal Respir. 2008: 25(5): 610-3. http://dx. doi. org/10. 1016/S0761-8425(08)71620-6.
10. Charniot JC, Vignat N, Monsuez JJ, Kidouche R, Avramova B, Artigou JY, et al. Cardiogenic shock associated with reversible dilated cardiomyopathy during therapy with regular doses of venlafaxine. Am J Emerg Med. 2010; 28(2): 256. e1-5.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2): 239-45. http://dx. doi. org/10. 1038/clpt. 1981. 154.
12. Khalifa M, Daleau P, Turgeon AJ. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocites. J Pharmacol Exp Ther. 1999; 291(1): 280-4.
13. Zhang JY, Wang Y, Prakash C. Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab. 2006; 7(8): 939-48. http://dx. doi. org/10. 2174/138920006779010575.
14. Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit. 2000; 22(2): 202-8. http://dx. doi. org/10. 1097/00007691-200004000-00011.
15. Eichelbaum M, Evert B. Influence of pharmacogenetics on drug disposition and response. Clin Exp Pharmacol Physiol. 1996; 23(10-11): 983-5. http://dx. doi. org/10. 1111/j. 1440-1681. 1996. tb01154. x.
16. Shams ME, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006; 31(5): 493-502. http://dx. doi. org/10. 1111/j. 1365-2710. 2006. 00763. x.
17. Pan Y, Abd-Rashid BA, Ismail Z, Ismail R, Mak JW, Pook PC, et al. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica. J Ethnopharmacol. 2010; 130(2): 275-83. http://dx. doi. org/10. 1016/j. jep. 2010. 05. 002.
18. Parys S, Kehraus S, Krick A, Glombitza KW, Carmeli S, Klimo K, et al. In vitro chemopreventive potential of fucophlorethols from the brown alga Fucus vesiculosus L. by anti-oxidant activity and inhibition of selected cytochrome P450 enzymes. Phytochemistry. 2010; 71(2-3): 221-9. http://dx. doi. org/10. 1016/j. phytochem. 2009. 10. 020.
19. Nonoyama T, Fukuda R. Drug-induced phospholipidosispathological aspects and its prediction. J Toxicol Pathol. 2008; 21(1): 9-24. http://dx. doi. org/10. 1293/tox. 21. 9.
20. Anderson N, Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006; 580(23): 5533-40. http://dx. doi. org/10. 1016/j. febslet. 2006. 08. 061.
21. Jamal MA, Bukhari IH, Muneer M, Shahzad K. Influence of external factors on self-aggregation of amphiphilic antidepressant drug: a thermodynamic study. J Chem Soc Pakistan. 2013; 35(2): 262-6.
22. Balasubramaniam J, Bindu K, Rao VU, Ray D, Haldar R, Brzeczko AW. Effect of superdisintegrants on dissolution of cationic drugs. Dissolut Technol. 2008; 15(2): 18-25.